Views & Analysis Breadth versus depth in R&D management Takeda’s Georgia Keresty is one of the only chief operating officers (COOs) for R&D in the industry.
News Takeda's Ninlaro falls short in first line multiple myeloma Takeda’s Ninlaro (ixazomib) has fallen short in a late-stage study testing it in combination with Bristol-Myers Squibb/Celgene’s Revlimid and chemo in newly diagnosed multiple myeloma.
News Takeda and Arcturus join hunt for coronavirus therapies The Japanese drugs giant Takeda and the US biotech Arcturus Therapeutics have joined the hunt for therapies for the COVID-19 coronavirus.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.